Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
14.77
+0.14 (0.96%)
At close: Aug 13, 2025, 4:00 PM
14.83
+0.06 (0.41%)
Pre-market: Aug 14, 2025, 9:09 AM EDT
Takeda Pharmaceutical Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
$654,374
Profits / Employee
$19,999
Market Cap
46.31B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
Mar 31, 2024 | 49,281 | 186 | 0.38% |
Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
Mar 31, 2022 | 47,347 | 248 | 0.53% |
Mar 31, 2021 | 47,099 | -396 | -0.83% |
Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
Mar 31, 2016 | 31,168 | -160 | -0.51% |
Mar 31, 2015 | 31,328 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TAK News
- 6 days ago - Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis - Newsfile Corp
- 14 days ago - Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales - Benzinga
- 14 days ago - Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression - Business Wire
- 24 days ago - Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration - Business Wire
- 27 days ago - Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector - Seeking Alpha
- 4 weeks ago - Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1 - Business Wire
- 6 weeks ago - Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 - Business Wire